On July 16, 2026, Eli Lilly and Company announced a definitive agreement to acquire clinical-stage biopharmaceutical developer AtaiBeckley N.V. in a transaction valued at up to $3.8 billion. The acquisition—comprising $6.75 per share in upfront cash (approximately $2.8 billion in equity value) plus contingent value rights (CVRs) of up to $2.50 per share (approximately $1.0 billion)—marks the largest single M&A commitment to psychedelic-based medicine by a major pharmaceutical corporation in history. Centered on AtaiBeckley's lead clinical asset BPL-003 (mebufotenin), a novel synthetic 5-MeO-DMT nasal spray formulation in Phase 2b/3 development for treatment-resistant depression (TRD), the deal signals a watershed transition: psychedelic therapeutics are moving from speculative venture-backed R&D into the core neuroscience growth strategies of global biopharma leaders.
+---------------------------------------------------------------------------------------------------+
| ELI LILLY / ATAIBECKLEY TRANSACTION STRUCTURE & PATHWAY |
+---------------------------------------------------------------------------------------------------+
| |
| UPFRONT CASH EQUITY VALUE CONTINGENT VALUE RIGHTS (CVR) |
| • $6.75 per share cash • Up to $2.50 per share cash |
| • Total Upfront: ~$2.8 Billion • Total CVR Value: ~$1.0 Billion |
| • 26% Premium to Spot ($5.36) • Tied to BPL-003 Pivotal Data & FDA Approval |
| • ~40% Premium to 30-Day VWAP • Expected Close: Q3 2026 |
| |
| │ │ |
| ▼ ▼ |
| ┌───────────────────────────────────────────────────────────────────────────────────────────┐ |
| │ TOTAL DEAL VALUE: UP TO $3.8 BILLION │ |
| └─────────────────────────────┬─────────────────────────────────────────────┘ |
| │ |
| ▼ |
| ┌─────────────────────────────────┐ |
| │ LEAD ASSET: BPL-003 │ |
| │ (Synthetic 5-MeO-DMT Nasal Spray)│ |
| └────────────────┬────────────────┘ |
| │ |
| ▼ |
| ┌───────────────────────────────────────────────────────────────────────────────────────────┐ |
| │ COMMERCIAL & PAYER ACCESS INFRASTRUCTURE │ |
| ├───────────────────────────────────────────────────────────────────────────────────────────┤ |
| │ • Spravato-Style REMS Protocol (Monitored In-Clinic Dosing) │ |
| │ • CPT Administration & Facility Coding Setup │ |
| │ • White House April 18, 2026 SMI Executive Order Policy Tailwinds │ |
| └───────────────────────────────────────────────────────────────────────────────────────────┘ |
+---------------------------------------------------------------------------------------------------+
Direct Commercial & Regulatory Answer
Why is Eli Lilly, the world's most valuable healthcare corporation, deploying up to $3.8 billion for a psychedelic drug developer, and what clinical and commercial hurdles must BPL-003 clear before reaching treatment-resistant depression patients?
Eli Lilly's acquisition of AtaiBeckley represents a calculated strategic expansion to reinforce its neuroscience division—balancing its dominant diabetes and obesity franchises (Eli Lilly portfolio dossier)—by capturing the leading late-stage asset in rapid-acting psychedelic psychiatry. Under the terms approved by both corporate boards, Lilly pays $6.75 per share in upfront cash (a 26% spot premium over the July 15 close of $5.36 and a 40% premium to its 30-day volume-weighted average price), with up to $2.50 per share in CVRs tied to Phase 3 initiation and to regulatory approval plus DEA rescheduling of the two lead assets, BPL-003 and VLS-01. To realize peak annual sales projected by sell-side analysts in the low single-digit billions, Lilly must not only demonstrate superior efficacy in pivotal Phase 3 trials, but also build out a certified clinic, REMS, and buy-and-bill reimbursement infrastructure modeled on J&J's Spravato (esketamine).
What are the exact terms of the Lilly-AtaiBeckley acquisition?
The transaction details filed with the SEC and released via primary distribution on July 16, 2026 outline a two-tier purchase structure designed to balance upfront enterprise value against milestone-gated development risk:
+---------------------------------------------------------------------------------------------------+
| LILLY-ATAIBECKLEY DEAL TERMS BREAKDOWN |
+------------------------------------+------------------------+--------------------+----------------+
| Component | Value Per Share | Total Equity Value | Premium / Basis|
+------------------------------------+------------------------+--------------------+----------------+
| Upfront Cash Consideration | $6.75 | ~$2.8 Billion | 26% vs Spot |
| 30-Day VWAP Premium | -- | -- | ~40% vs VWAP |
| Contingent Value Right (CVR) Max | $2.50 | ~$1.0 Billion | Milestone-Based|
| Maximum Potential Deal Value | $9.25 | ~$3.8 Billion | Combined Max |
+---------------------------------------------------------------------------------------------------+
Upfront Cash Equity Value
Lilly will acquire all outstanding common shares of AtaiBeckley for $6.75 per share in cash upon closing, representing an upfront equity purchase price of approximately $2.8 billion. The upfront offer reflects a 26% premium over AtaiBeckley's closing price of $5.36 on July 15, 2026, and an approximate 40% premium over its 30-day volume-weighted average price (VWAP).
CVR Milestone Mechanics
In addition to upfront cash, AtaiBeckley shareholders will receive one non-tradeable CVR per share, entitling holders to receive up to an additional $2.50 per share in cash (aggregating to approximately $1.0 billion across all fully diluted shares) upon the achievement of pre-specified clinical and regulatory milestones. Notably, the CVR milestones are tied to regulatory approval and DEA rescheduling, and span both lead psychedelic assets—not BPL-003 alone:
- Milestone 1 ($1.00 per share / ~$400 million): Initiation of a Phase 3 clinical trial of VLS-01 (DMT buccal film) prior to the fourth anniversary of closing.
- Milestone 2 ($0.50 per share / ~$200 million): U.S. regulatory approval and DEA rescheduling of BPL-003 prior to the fifth anniversary of closing.
- Milestone 3 ($1.00 per share / ~$400 million): U.S. regulatory approval and DEA rescheduling of VLS-01 prior to the seventh anniversary of closing.
Lilly cautioned that "there can be no assurance that any payments will be made with respect to the CVR." The structure signals that the headline BPL-003 asset carries the smallest single CVR payment ($0.50), while the larger contingent value is back-loaded onto VLS-01 development and the shared DEA-scheduling hurdle that any Schedule I-derived therapeutic must clear.
The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions, including antitrust clearance under the Hart-Scott-Rodino (HSR) Act and approval by AtaiBeckley stockholders.
Context Within Lilly's 2026 Capital Deployment Spree
This acquisition is the latest in a run of large Eli Lilly business-development moves through 2026. With substantial cash flow generated by its incretin franchise (Mounjaro/Zepbound), Lilly has used its balance sheet to rebuild its neuroscience, immunology, and genetic-medicine pipelines, placing it among the most active big-pharma acquirers of the year (biopharma M&A deals by the numbers 2026).
What is BPL-003, how does mebufotenin work, and when does it read out?
BPL-003 (mebufotenin benzoate) is a proprietary synthetic formulation of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) administered as an intranasal spray.
+---------------------------------------------------------------------------------------------------+
| BPL-003 (MEBUFETENIN) ASSET PROFILE & TIMELINE |
+---------------------------------------------------------------------------------------------------+
| Feature | Detail / Clinical Specification |
+------------------------------------+--------------------------------------------------------------+
| Active Pharmaceutical Ingredient | Mebufotenin benzoate (synthetic 5-MeO-DMT) |
| Primary Pharmacological Mechanism | 5-HT1A and 5-HT2A receptor agonist |
| Route of Administration | Intranasal formulation |
| Target Clinical Indication | Treatment-Resistant Depression (TRD) |
| Acute Effect & Clinic Visit | Rapid psychedelic onset; monitored in-clinic visit ~2 hours |
| Current Clinical Status | Phase 2 complete; Phase 3 activities initiated |
| Regulatory Designation | FDA Breakthrough Therapy Designation |
| Sell-Side Peak Sales Outlook | Low single-digit billions (analyst estimates) |
+---------------------------------------------------------------------------------------------------+
Pharmacological Mechanism
Mebufotenin is a naturally occurring indolealkylamine (5-methoxy-N,N-dimethyltryptamine) formulated as a benzoate salt for intranasal delivery. Like other classical psychedelics, it acts as an agonist at serotonin 5-HT2A receptors—thought to underlie its acute subjective effects and downstream cortical neuroplasticity—and also shows affinity for 5-HT1A receptors. Relative to long-acting psychedelics such as psilocybin or LSD, 5-MeO-DMT is notable for its very rapid onset and short duration of acute effect, which is the core operational attraction for clinic-based dosing: a brief, observable treatment session rather than an all-day infusion of staff time.
Phase 2 Efficacy & Durability Findings
BPL-003's clinical package rests on a Phase 2 dose-finding study (ClinicalTrials.gov NCT05870540, "A Quadruple Masked, Dose-Finding Study to Evaluate the Efficacy and Safety of Intranasal BPL-003... in Patients With Treatment-Resistant Depression," sponsored by Beckley Psytech) plus open-label extension data. Across Phase 2a/2b readouts, AtaiBeckley reported:
- Rapid Onset: Improvements in Montgomery-Åsberg Depression Rating Scale (MADRS) scores appeared as early as Day 2 following a single in-clinic dose.
- Durability: Antidepressant effects were durable through Week 8, with a second dose at Week 2 showing potential to deepen response.
- Remission-Level Improvements: Among 12 mg responders, mean MADRS scores fell from the high teens (~19–21) into the remission range (~6–9), with sustained symptom reduction.
- Tolerability: The 12 mg intranasal dose was generally well-tolerated, and the in-clinic visit lasted approximately two hours on average. Phase 2a results were published in CNS Drugs.
BPL-003 has received FDA Breakthrough Therapy Designation, and AtaiBeckley has initiated Phase 3 activities.
How does this deal compare with prior psychedelic transactions (Otsuka-Transcend, AbbVie)?
Lilly's acquisition of AtaiBeckley represents the pinnacle of a multi-year consolidation wave in neuro-psychiatry. Over the past several years, major biopharma companies have systematically moved from early research collaborations to multi-billion-dollar outright corporate buyouts.
+---------------------------------------------------------------------------------------------------+
| COMPARATIVE MAJOR BIOPHARMA PSYCHEDELIC M&A TRANSACTIONS |
+---------------------------------------------------------------------------------------------------+
| Acquirer | Target / Partner | Lead Asset / Modality | Total Value | Announcement |
+-----------------+--------------------+-----------------------------+----------------+----------------+
| Eli Lilly | AtaiBeckley N.V. | BPL-003 (5-MeO-DMT, nasal) | Up to $3.8B | July 16, 2026 |
| Otsuka Pharma | Transcend Therap. | TSND-201 (Methylone, PTSD) | Up to $1.225B | March 2026 |
| AbbVie | Gilgamesh Pharma | Neuroplastogen platform | Up to ~$2B | May 13, 2024 |
| | | (lead candidate bretisilocin;| (+ up to $1.2B | (+ Aug 25, 2025|
| | | MDD asset acquired 2025) | 2025 asset buy)| asset option) |
+-----------------+--------------------+-----------------------------+----------------+----------------+
Two distinctions matter for deal-watchers. First, Otsuka's Transcend transaction is larger than headlines suggest: the widely cited $700 million is only the upfront payment at closing, with up to $525 million in milestones bringing the total to about $1.225 billion for TSND-201 (methylone, developed for PTSD). Second, AbbVie's Gilgamesh relationship is a two-stage structure—an initial May 2024 neuroplastogen collaboration/option worth up to roughly $2 billion ($65 million upfront plus milestones), followed by an August 2025 exercise to acquire the lead candidate bretisilocin for up to about $1.2 billion. Lilly's AtaiBeckley pact is the largest single psychedelic-franchise commitment by total potential value.
Strategic Validation of the Modality
As documented in our global analysis of the psychedelic-assisted therapy pipeline 2026 by the numbers, early venture funding for psychedelic biotech dried up following high-profile regulatory setbacks. Lilly's willingness to fund AtaiBeckley at a $3.8 billion valuation confirms that major pharma balance sheets are now stepping in to finance expensive late-stage Phase 3 trials and commercialize neuro-psychedelic assets.
Portfolio Rationalization for AtaiBeckley's Non-Core Assets
Beyond BPL-003, the AtaiBeckley pipeline includes VLS-01 (a DMT buccal film in Phase 2b for TRD) and EMP-01 ((R)-MDMA in Phase 2 for social anxiety disorder), plus a discovery program for novel, non-hallucinogenic 5-HT2A-receptor agonists. The CVR structure signals that Lilly attaches real option value to VLS-01 specifically—two of the three CVR milestones ($2.00 of the $2.50 per share) are tied to VLS-01 Phase 3 initiation and approval-plus-DEA-rescheduling—while BPL-003 carries the remaining $0.50 milestone.
What payer-access and REMS-style infrastructure will a psychedelic for TRD require?
While acquiring BPL-003 secures late-stage intellectual property, commercializing an intranasal psychedelic for depression requires overcoming complex site-of-service, risk management, and reimbursement constraints.
+---------------------------------------------------------------------------------------------------+
| SPRAVATO vs BPL-003 COMMERCIAL & ACCESS COMPARISON |
+--------------------------------+----------------------------------+-------------------------------+
| Commercial Dimension | Spravato (Esketamine - J&J) | BPL-003 (Mebufotenin - Lilly) |
+--------------------------------+----------------------------------+-------------------------------+
| Administration Time | ~2 Hours In-Clinic Observation | ~2 Hours (acute effect briefer)|
| Dosing Frequency | Twice Weekly -> Maintenance | Single Dose -> Intermittent |
| REMS Distribution Requirement | Mandatory ETASU Certified Sites | Anticipated ETASU Certified |
| Buy-and-Bill HCPCS Code | S0013 / J3490 Unclassified | Future J-Code Assignment |
| In-Clinic Monitoring CPT Code | G2082 / G2083 Physician Time | Adapted Monitoring CPT Codes |
+---------------------------------------------------------------------------------------------------+
The Spravato Blueprint: REMS and Facility Certification
Lilly's commercialization strategy will draw heavily from J&J's experience establishing the market for Spravato (esketamine), detailed in our Spravato esketamine REMS coverage guide. FDA will almost certainly mandate a Risk Evaluation and Mitigation Strategy (REMS) with Elements to Assure Safe Use (ETASU) for BPL-003:
- Medication Administration: BPL-003 must be dispensed and administered directly to patients in certified healthcare settings (clinics, hospital outpatient departments) under the direct supervision of a healthcare provider.
- Post-Dose Monitoring: Patients must be monitored for blood pressure spikes, dissociation, and acute psychological distress until medical resolution. AtaiBeckley reported that the in-clinic visit for BPL-003 lasted approximately two hours on average; although 5-MeO-DMT's acute psychedelic effect is briefer than esketamine's dissociative window, the monitored stay remains a chair-time- and staff-intensive event.
- Distribution Restrictions: Product cannot be dispensed directly to patients for home use; distribution occurs strictly through specialized buy-and-bill or specialty pharmacy specialty channels.
Outpatient Clinic Capacity & Throughput Economics
For interventional psychiatry clinics, the operational appeal of BPL-003 is not yet locked in and depends on the final label and REMS. The key open variable is monitoring duration: Spravato's REMS currently requires a roughly two-hour post-dose observation, which caps chair throughput. AtaiBeckley's Phase 2 protocol used an in-clinic visit of approximately two hours on average, so the operational economics will turn on whether the FDA-approved label and REMS allow a meaningfully shorter monitored recovery than esketamine.
+---------------------------------------------------------------------------------------------------+
| CLINIC THROUGHPUT DRIVERS: SPRAVATO vs A POTENTIAL BPL-003 LABEL |
+------------------------------------+------------------------------+--------------------------------+
| Operational Lever | Spravato (Esketamine) REMS | BPL-003 (Mebufotenin) — Open |
| | (current) | Questions for the Label/REMS |
+------------------------------------+------------------------------+--------------------------------+
| Mandatory post-dose observation | ~2 hours | TBD — acute effect is shorter, |
| | | but Phase 2 visit was ~2 hrs |
| Chairs per patient per session | 1 chair, blocked ~2 hrs | Could fall if label permits |
| | | shorter monitored recovery |
| Staffing requirement | Certified site, onsite | Expected: certified site, |
| | provider monitoring | onsite provider monitoring |
| Dosing cadence | Induction twice weekly, | Single/intermittent dose model |
| | then maintenance | proposed |
+------------------------------------+------------------------------+--------------------------------+
If the final REMS permits a materially shorter monitored window than esketamine's, BPL-003 could raise daily chair throughput and lower per-session nursing cost—making interventional centers eager adopters once payer coverage is established. If the REMS mandates comparable two-hour monitoring, the throughput advantage narrows and the commercial case rests on efficacy and durability instead.
What pipeline risks and failure scenarios must Eli Lilly manage before BPL-003 reaches market?
Despite the compelling $3.8 billion transaction value, Eli Lilly faces substantial clinical, regulatory, and commercial execution risks before BPL-003 can achieve commercial profitability:
+---------------------------------------------------------------------------------------------------+
| BPL-003 RISK MATRIX & MITIGATION STRATEGY |
+---------------------------------------------------------------------------------------------------+
| Risk Category | Primary Failure Mechanism | Lilly Corporate Mitigation Strategy |
+---------------------------+--------------------------------+--------------------------------------+
| Functional Unblinding | Intense acute trip experience | Use active low-dose mebufotenin |
| (Clinical Trial Design) | breaks placebo control in Ph3 | control arm in Phase 3 trials |
+---------------------------+--------------------------------+--------------------------------------+
| Psych-Assisted Therapy | FDA reluctance to approve | Position BPL-003 as standalone drug |
| Requirement Controversy | co-packaged psychotherapy | without mandatory psychotherapy |
+---------------------------+--------------------------------+--------------------------------------+
| DEA Schedule Administrative| Delay between FDA approval and | Leverage the April 18, 2026 Executive |
| Delay | DEA Schedule II/III placement | Order directing FDA/DEA to coordinate |
| | | a patient-access pathway (incl. Right |
| | | to Try) for serious mental illness |
+---------------------------+--------------------------------+--------------------------------------+
| Payer Step-Therapy Mandates| Restrictive formulary tiers | Generate head-to-head health economic|
| | requiring 3+ prior failures | data vs esketamine and rTMS |
+---------------------------------------------------------------------------------------------------+
Lessons from the 2024 Lykos MDMA Rejection
The FDA's August 2024 Complete Response Letter (CRL) for Lykos Therapeutics' MDMA-assisted psychotherapy highlighted critical regulatory landmines that Lilly's regulatory team must navigate:
- Separation of Drug from Psychotherapy: FDA expressed deep skepticism regarding BLA filings where drug efficacy is confounded by non-standardized psychological counseling. Lilly has designed BPL-003 Phase 3 protocols as a standalone pharmaceutical intervention requiring medical monitoring rather than formal psychotherapy.
- Functional Unblinding: In clinical trials of potent psychedelics, patients and raters immediately identify active treatment vs inert placebo. To mitigate unblinding bias, Lilly will utilize a sub-psychoactive active dose of mebufotenin as the control comparator in Phase 3.
Corporate M&A Valuation & Earnings Impact for Eli Lilly
From a corporate finance perspective, Eli Lilly's up to $3.8 billion commitment ($2.8 billion upfront) is small relative to the cash generation of its incretin franchise (Mounjaro/Zepbound), which has made Lilly one of the most cash-rich companies in healthcare. The transaction is therefore notable less for its near-term earnings impact than for what it signals about how Lilly is recycling diabetes/obesity cash into adjacent central-nervous-system franchises.
+---------------------------------------------------------------------------------------------------+
| ELI LILLY / ATAIBECKLEY DEAL-ECONOMICS FRAMEWORK |
+------------------------------------+--------------------------------------------------------------+
| Deal-Economics Parameter | Assessment |
+------------------------------------+--------------------------------------------------------------+
| Upfront cash outlay | ~$2.8B equity ($6.75/share) |
| Contingent consideration (CVR max) | ~$1.0B ($2.50/share), largely milestone- and DEA-gated |
| What Lilly is paying for | Late-stage 5-MeO-DMT asset (BPL-003) + VLS-01 + platform |
| Near-term P&L impact | Acquired in-process R&D charge at close; no near-term revenue|
| Value-realization trigger | Phase 3 success + FDA approval + DEA rescheduling |
| Strategic logic | Convert incretin cash flow into a 2030s neuroscience franchise|
+------------------------------------+--------------------------------------------------------------+
Because the CVR payments are conditional on development and regulatory milestones that are years away, the deal is structurally a low-cash-risk option on a psychedelic-neuroscience platform—if the assets fail, Lilly's downside is largely the upfront $2.8 billion.
Why now: does the April 2026 White House serious-mental-illness order change the calculus?
The timing of Lilly's acquisition was heavily influenced by federal policy tailwinds. On April 18, 2026, the White House issued Executive Order 14401, Accelerating Medical Treatments for Serious Mental Illness. Per the order and accompanying fact sheet, the directive directs FDA and DEA to "facilitate and establish" a coordinated pathway for patients to access psychedelic-assisted therapies, including through Right to Try provisions, and to expand researcher access to psychedelic compounds for psychiatric conditions. In practical terms for a developer like AtaiBeckley, the order:
- Signals executive-branch intent to coordinate FDA review and DEA scheduling hand-offs for Schedule I–derived therapeutics, rather than leaving sponsors to navigate the two agencies sequentially.
- Leverages Right to Try as a potential early-access channel for patients with serious mental illness, which could expand the addressable population ahead of full commercial launch.
- Reduces (without eliminating) the DEA-rescheduling uncertainty that has historically deterred big-pharma capital from the psychedelic class.
This executive direction reduced a meaningful layer of regulatory uncertainty, supporting Lilly's willingness to deploy $2.8 billion in upfront capital.
Action Matrix for BD Teams and Managed Care Planners
+---------------------------------------------------------------------------------------------------+
| RECOMMENDED ACTION MATRIX FOR TRADE STAKEHOLDERS |
+---------------------------------------------------------------------------------------------------+
| Stakeholder Group | Strategic Focus Area | Immediate Recommended Action |
+-----------------------------+--------------------------------+------------------------------------+
| Biopharma BD & Strategy | Category Consolidation | • Benchmark remaining 5-HT2A/5-HT1A|
| | | psych-assets for M&A window |
+-----------------------------+--------------------------------+------------------------------------+
| Payer Medical Directors | Formulating Interventional Tier| • Assess Spravato REMS utilization |
| | | data to model 2029 BPL-003 impact|
+-----------------------------+--------------------------------+------------------------------------+
| Interventional Clinics | Facility Infrastructure | • Build out 60-minute recovery |
| | | bays for short-acting synthetics |
+-----------------------------+--------------------------------+------------------------------------+
Frequently Asked Questions (FAQ)
Is the Lilly-AtaiBeckley deal the largest psychedelic pharma transaction to date?
Yes. At a total potential value of up to $3.8 billion ($2.8 billion upfront cash), it surpasses all prior transactions in the psychedelic and neuro-psychiatry biotech space.
Will BPL-003 require a REMS and monitored dosing like Spravato (esketamine)?
Yes. Due to the acute alter-state effects of mebufotenin (5-MeO-DMT), FDA approval is expected to require certified healthcare facility administration and provider monitoring. 5-MeO-DMT's acute psychedelic effect is shorter-acting than esketamine's dissociative window, though AtaiBeckley's Phase 2 in-clinic visit still lasted about two hours on average—the final required monitoring window will be set by the label and REMS.
When does BPL-003 report pivotal data and what is the earliest potential approval?
AtaiBeckley has initiated Phase 3 activities for BPL-003. The deal's CVR terms give a concrete contractual timeline anchor: the BPL-003 approval-and-DEA-rescheduling milestone must be achieved before the fifth anniversary of closing, implying a target U.S. approval no later than roughly 2031 (with a Q3 2026 close).
How does mebufotenin differ from oral psilocybin in clinical administration?
Mebufotenin (5-MeO-DMT) is administered as an intranasal formulation and has a comparatively brief acute psychedelic effect, whereas oral psilocybin produces a multi-hour experience (typically 6 to 8 hours) requiring a correspondingly longer in-clinic monitoring session.
What happens to AtaiBeckley's non-psychedelic pipeline assets post-acquisition?
Eli Lilly intends to focus resources on lead psychedelic assets BPL-003 and VLS-01, while pursuing out-licensing, spin-out, or strategic divestment structures for non-core schizophrenia and neurology programs following closing.
How will commercial health plans cover BPL-003 during the initial launch phase?
Commercial payers are expected to place BPL-003 on specialty medical tiers requiring prior authorization (mandating failure of two or more oral antidepressants and one trial of esketamine or rTMS) under buy-and-bill medical benefit coverage.
Sources
- Eli Lilly and Company. Lilly to Acquire AtaiBeckley to Advance Therapies for Treatment-Resistant Depression and Other Mental Health Conditions. Primary Press Release, PRNewswire, July 16, 2026. https://www.prnewswire.com/news-releases/lilly-to-acquire-ataibeckley-to-advance-therapies-for-treatment-resistant-depression-and-other-mental-health-conditions-302827468.html
- ClinicalTrials.gov. A Quadruple Masked, Dose-Finding Study to Evaluate the Efficacy and Safety of Intranasal BPL-003 in Patients With Treatment-Resistant Depression (NCT05870540). Sponsor: Beckley Psytech Limited. https://clinicaltrials.gov/study/NCT05870540
- The White House. Executive Order 14401: Accelerating Medical Treatments for Serious Mental Illness. Presidential Actions, April 18, 2026. https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/
- Reuters. Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal. Healthcare & Pharmaceuticals, July 16, 2026. https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enters-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16
- BioPharma Dive. Lilly to buy AtaiBeckley for $2.8B upfront, further validating psychedelics. July 16, 2026. https://www.biopharmadive.com/news/lilly-ataibeckley-psychedelics-acquisition-deal-mebufotenin-depression/825425
- CNBC. Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion in cash. July 16, 2026. https://www.cnbc.com/2026/07/16/eli-lilly-to-buy-psychedelics-maker-ataibeckley-2point8-billion.html
- Transcend Therapeutics / Otsuka. Otsuka Pharmaceutical to Acquire Transcend Therapeutics (up to $1.225B; $700M upfront). March 2026. https://transcendtherapeutics.com/otsuka-pharmaceutical-to-acquire-transcend-therapeutics/
- AbbVie. AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement (up to ~$2B), May 13, 2024; AbbVie to Acquire Gilgamesh's Bretisilocin (up to ~$1.2B), Aug 25, 2025. https://news.abbvie.com/2024-05-13-AbbVie-and-Gilgamesh-Pharmaceuticals-Announce-Collaboration-and-Option-to-License-Agreement-to-Develop-Next-Generation-Therapies-for-Psychiatric-Disorders
